Interleukin-1 inhibitors for acute gout

Sivera, Francisca; Wechalekar, Mihir D.; Andrés, Mariano; Buchbinder, Rachelle; Carmona, Loreto

doi:10.1002/14651858.cd009993.pub2

Cited by 30 publications

(26 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twenty-six trials were included on treatment of acute gout flares (21 evaluated non-steroidal anti-inflammatory drugs (NSAIDs),45 five glucocorticoids,46 two colchicine, and one canakinumab47). The available evidence showed that low-dose colchicine (total dose 1.8 mg in 24 h) was more effective than placebo48 49 and as effective as high-dose colchicine (total dose 4.8 mg), but lower doses of colchicine had a significantly better safety profile 49.…”

Section: Resultsmentioning

confidence: 99%

Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative

et al. 2013

Self Cite

View full text Add to dashboard Cite

We aimed to develop evidence-based multinational recommendations for the diagnosis and management of gout. Using a formal voting process, a panel of 78 international rheumatologists developed 10 key clinical questions pertinent to the diagnosis and management of gout. Each question was investigated with a systematic literature review. Medline, Embase, Cochrane CENTRAL and abstracts from 2010–2011 European League Against Rheumatism and American College of Rheumatology meetings were searched in each review. Relevant studies were independently reviewed by two individuals for data extraction and synthesis and risk of bias assessment. Using this evidence, rheumatologists from 14 countries (Europe, South America and Australasia) developed national recommendations. After rounds of discussion and voting, multinational recommendations were formulated. Each recommendation was graded according to the level of evidence. Agreement and potential impact on clinical practice were assessed. Combining evidence and clinical expertise, 10 recommendations were produced. One recommendation referred to the diagnosis of gout, two referred to cardiovascular and renal comorbidities, six focused on different aspects of the management of gout (including drug treatment and monitoring), and the last recommendation referred to the management of asymptomatic hyperuricaemia. The level of agreement with the recommendations ranged from 8.1 to 9.2 (mean 8.7) on a 1–10 scale, with 10 representing full agreement. Ten recommendations on the diagnosis and management of gout were established. They are evidence-based and supported by a large panel of rheumatologists from 14 countries, enhancing their utility in clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that interleukin-1 is an important mediator of inflammation in acute gout. According to a Cochrane review (24), interleukin-1 antagonists can be considered as an alternative option if all 3 standard treatment options are contraindicated or not tolerated (B).…”

Section: Commentsmentioning

confidence: 99%

Treatment Options for Gout

Engel

Just²,

Bleckwenn³

et al. 2017

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

show abstract

“…23 Canakinumab treatment is expensive (£9,928/dose). 24 The National Institute for Health and Care Excellence (NICE) has not published guidance on canakinumab’s use.…”

Section: Treatment Of Acute Goutmentioning

confidence: 99%

An update on the management of gout

2018

DTB

View full text Add to dashboard Cite

Gout is the most common form of inflammatory arthritis and its incidence in the UK has steadily increased from 1.5% in 1997 to 2.5% in 2012. It is characterised by deposition of monosodium urate crystals in joints and tissues and usually presents with intermittent painful attacks followed by long periods of remission. It has been suggested that the management of gout in the UK remains suboptimal. In 2004, we concluded that there was a woeful lack of evidence to guide treatment or prophylaxis for gout, particularly with regard to choice of drug or doses. The introduction of new drugs and new evidence on the efficacy and safety of treatment options has led the European League Against Rheumatism (EULAR) and the British Society of Rheumatology (BSR) to update their guidelines on the management of gout. Nevertheless, there are differing views on target serum uric acid (SUA) levels and the role of urate lowering treatment (ULT). Here, we review the latest guidance on the management of gout and consider the role of long-term ULT.

show abstract

Interleukin-1 inhibitors for acute gout

Cited by 30 publications

References 23 publications

Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative

Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative

Treatment Options for Gout

An update on the management of gout

Contact Info

Product

Resources

About